Hematopoietic differentiation is characterized by a transient peak of entropy at a single-cell level.


Journal

BMC biology
ISSN: 1741-7007
Titre abrégé: BMC Biol
Pays: England
ID NLM: 101190720

Informations de publication

Date de publication:
09 03 2022
Historique:
received: 24 08 2021
accepted: 22 02 2022
entrez: 9 3 2022
pubmed: 10 3 2022
medline: 15 4 2022
Statut: epublish

Résumé

Mature blood cells arise from hematopoietic stem cells in the bone marrow by a process of differentiation along one of several different lineage trajectories. This is often represented as a series of discrete steps of increasing progenitor cell commitment to a given lineage, but as for differentiation in general, whether the process is instructive or stochastic remains controversial. Here, we examine this question by analyzing single-cell transcriptomic data from human bone marrow cells, assessing cell-to-cell variability along the trajectories of hematopoietic differentiation into four different types of mature blood cells. The instructive model predicts that cells will be following the same sequence of instructions and that there will be minimal variability of gene expression between them throughout the process, while the stochastic model predicts a role for cell-to-cell variability when lineage commitments are being made. Applying Shannon entropy to measure cell-to-cell variability among human hematopoietic bone marrow cells at the same stage of differentiation, we observed a transient peak of gene expression variability occurring at characteristic points in all hematopoietic differentiation pathways. Strikingly, the genes whose cell-to-cell variation of expression fluctuated the most over the course of a given differentiation trajectory are pathway-specific genes, whereas genes which showed the greatest variation of mean expression are common to all pathways. Finally, we showed that the level of cell-to-cell variation is increased in the most immature compartment of hematopoiesis in myelodysplastic syndromes. These data suggest that human hematopoietic differentiation could be better conceptualized as a dynamical stochastic process with a transient stage of cellular indetermination, and strongly support the stochastic view of differentiation. They also highlight the need to consider the role of stochastic gene expression in complex physiological processes and pathologies such as cancers, paving the way for possible noise-based therapies through epigenetic regulation.

Sections du résumé

BACKGROUND
Mature blood cells arise from hematopoietic stem cells in the bone marrow by a process of differentiation along one of several different lineage trajectories. This is often represented as a series of discrete steps of increasing progenitor cell commitment to a given lineage, but as for differentiation in general, whether the process is instructive or stochastic remains controversial. Here, we examine this question by analyzing single-cell transcriptomic data from human bone marrow cells, assessing cell-to-cell variability along the trajectories of hematopoietic differentiation into four different types of mature blood cells. The instructive model predicts that cells will be following the same sequence of instructions and that there will be minimal variability of gene expression between them throughout the process, while the stochastic model predicts a role for cell-to-cell variability when lineage commitments are being made.
RESULTS
Applying Shannon entropy to measure cell-to-cell variability among human hematopoietic bone marrow cells at the same stage of differentiation, we observed a transient peak of gene expression variability occurring at characteristic points in all hematopoietic differentiation pathways. Strikingly, the genes whose cell-to-cell variation of expression fluctuated the most over the course of a given differentiation trajectory are pathway-specific genes, whereas genes which showed the greatest variation of mean expression are common to all pathways. Finally, we showed that the level of cell-to-cell variation is increased in the most immature compartment of hematopoiesis in myelodysplastic syndromes.
CONCLUSIONS
These data suggest that human hematopoietic differentiation could be better conceptualized as a dynamical stochastic process with a transient stage of cellular indetermination, and strongly support the stochastic view of differentiation. They also highlight the need to consider the role of stochastic gene expression in complex physiological processes and pathologies such as cancers, paving the way for possible noise-based therapies through epigenetic regulation.

Identifiants

pubmed: 35260165
doi: 10.1186/s12915-022-01264-9
pii: 10.1186/s12915-022-01264-9
pmc: PMC8905725
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

60

Informations de copyright

© 2022. The Author(s).

Références

Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Cancers (Basel). 2019 Feb 13;11(2):
pubmed: 30781877
PLoS Comput Biol. 2019 Jun 5;15(6):e1007034
pubmed: 31166947
Trends Genet. 2020 Apr;36(4):288-297
pubmed: 32035656
PLoS One. 2014 Dec 22;9(12):e115574
pubmed: 25531401
Cell Stem Cell. 2013 Oct 3;13(4):492-505
pubmed: 24035353
BMC Genomics. 2018 Jun 19;19(1):477
pubmed: 29914354
Haematologica. 2014 Apr;99(4):638-46
pubmed: 24463214
Cell. 2020 Sep 17;182(6):1384-1400
pubmed: 32946781
Nat Commun. 2019 Jun 3;10(1):2395
pubmed: 31160568
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
PLoS Biol. 2019 Oct 15;17(10):e3000433
pubmed: 31613873
Nature. 2000 Sep 21;407(6802):383-6
pubmed: 11014194
Cell Syst. 2017 Nov 22;5(5):471-484.e4
pubmed: 29102610
Stem Cells. 2018 Dec;36(12):1828-1838
pubmed: 30270482
Nat Biotechnol. 2019 Apr;37(4):451-460
pubmed: 30899105
Nat Rev Genet. 2019 Sep;20(9):536-548
pubmed: 31114032
Science. 2009 Jul 10;325(5937):217-8
pubmed: 19590005
Genome Biol. 2018 Feb 6;19(1):15
pubmed: 29409532
Mol Cell. 2016 Jun 2;62(5):788-802
pubmed: 27259209
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Nature. 2018 Jan 24;553(7689):418-426
pubmed: 29364285
Elife. 2020 Jan 27;9:
pubmed: 31985402
Exp Hematol. 2018 Dec;68:51-61
pubmed: 30243574
Nat Commun. 2017 Oct 23;8(1):1096
pubmed: 29061959
N Engl J Med. 2009 Nov 5;361(19):1872-85
pubmed: 19890130
Nat Rev Genet. 2021 Apr;22(4):235-250
pubmed: 33244170
PLoS Biol. 2016 Dec 27;14(12):e2000640
pubmed: 28027308
Nature. 2008 May 22;453(7194):544-7
pubmed: 18497826
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Genome Biol. 2018 Jun 19;19(1):78
pubmed: 29921301
Nat Biotechnol. 2019 Dec;37(12):1458-1465
pubmed: 31792411
Science. 2017 Jul 21;357(6348):
pubmed: 28729483
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Haematologica. 2019 Oct;104(10):1919-1927
pubmed: 31515352
PLoS Biol. 2009 Jul;7(7):e1000149
pubmed: 19582141
PLoS Comput Biol. 2017 Jun 30;13(6):e1005585
pubmed: 28665997
PLoS Biol. 2016 Dec 27;14(12):e1002585
pubmed: 28027290
Cell. 2008 Oct 17;135(2):216-26
pubmed: 18957198
Genetics. 2018 Jan;208(1):173-189
pubmed: 29097405
Nat Methods. 2017 Sep 29;14(10):935-936
pubmed: 28960196
Nature. 2009 Sep 10;461(7261):183-4
pubmed: 19741696
Front Cell Dev Biol. 2019 Jun 18;7:104
pubmed: 31275935
PLoS One. 2019 Nov 21;14(11):e0225166
pubmed: 31751364
Nat Rev Genet. 2021 Jul;22(7):459-476
pubmed: 33875884
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Cell Syst. 2017 Sep 27;5(3):268-282.e7
pubmed: 28957659
Interface Focus. 2018 Dec 6;8(6):20180040
pubmed: 30443337
Nat Commun. 2021 Mar 1;12(1):1366
pubmed: 33649320
Cell. 2017 Jul 27;170(3):577-592.e10
pubmed: 28753431
Nat Commun. 2018 Jan 24;9(1):345
pubmed: 29367605
Rheumatology (Oxford). 2022 Feb 2;61(2):775-780
pubmed: 33836046
Blood. 1998 Jul 15;92(2):348-51; discussion 352
pubmed: 9657728
Genome Biol. 2019 Oct 17;20(1):210
pubmed: 31623682
PLoS Biol. 2017 Jul 27;15(7):e2001867
pubmed: 28749943
Nature. 2020 Jul;583(7816):431-436
pubmed: 32581360
Blood. 2017 Jan 26;129(4):484-496
pubmed: 27856460
Nat Biotechnol. 2015 May;33(5):495-502
pubmed: 25867923

Auteurs

Charles Dussiau (C)

Institut Cochin, CNRSUMR8104, INSERM U1016, OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Université de Paris, Paris, France.
Assistance Publique-Hôpitaux de Paris, Centre - Université de Paris, Service d'Hématologie biologique, Hôpital Cochin, Paris, France.

Agathe Boussaroque (A)

Institut Cochin, CNRSUMR8104, INSERM U1016, OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Université de Paris, Paris, France.

Mathilde Gaillard (M)

ENS de Lyon, Université Claude Bernard, CNRS UMR 5239, INSERM U1210, Laboratory of Biology and Modelling of the Cell, Université de Lyon, 46 allée d'Italie Site Jacques Monod, F-69007, Lyon, France.

Clotilde Bravetti (C)

Institut Cochin, CNRSUMR8104, INSERM U1016, OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Université de Paris, Paris, France.

Laila Zaroili (L)

Institut Cochin, CNRSUMR8104, INSERM U1016, OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Université de Paris, Paris, France.

Camille Knosp (C)

Institut Cochin, CNRSUMR8104, INSERM U1016, OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Université de Paris, Paris, France.

Chloé Friedrich (C)

Institut Cochin, CNRSUMR8104, INSERM U1016, OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Université de Paris, Paris, France.
Assistance Publique-Hôpitaux de Paris, Centre - Université de Paris, Service d'Hématologie biologique, Hôpital Cochin, Paris, France.

Philippe Asquier (P)

Pole Sante Leonard de Vinci, Chambray Les Tours, France.

Lise Willems (L)

Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France.

Laurent Quint (L)

Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France.
Hôpital Américain de Paris, 63 boulevard Victor Hugo, 92200, Neuilly-sur-Seine, France.

Didier Bouscary (D)

Institut Cochin, CNRSUMR8104, INSERM U1016, OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Université de Paris, Paris, France.
Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France.

Michaela Fontenay (M)

Institut Cochin, CNRSUMR8104, INSERM U1016, OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Université de Paris, Paris, France.
Assistance Publique-Hôpitaux de Paris, Centre - Université de Paris, Service d'Hématologie biologique, Hôpital Cochin, Paris, France.

Thibault Espinasse (T)

Université Lyon 1, CNRS UMR5208, Institut Camille Jordan, Université de Lyon, 43 blvd. du 11 novembre 1918, F-69622, Villeurbanne Cedex, France.
Inria Team Dracula, Inria Center Grenoble Rhône-Alpes, Montbonnot-Saint-Martin, France.

Adriana Plesa (A)

Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'Hématologie Biologique, Pierre-Bénite, France.
Cancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Lyon, France.

Pierre Sujobert (P)

Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'Hématologie Biologique, Pierre-Bénite, France.
Cancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Lyon, France.

Olivier Gandrillon (O)

ENS de Lyon, Université Claude Bernard, CNRS UMR 5239, INSERM U1210, Laboratory of Biology and Modelling of the Cell, Université de Lyon, 46 allée d'Italie Site Jacques Monod, F-69007, Lyon, France.
Inria Team Dracula, Inria Center Grenoble Rhône-Alpes, Montbonnot-Saint-Martin, France.

Olivier Kosmider (O)

Institut Cochin, CNRSUMR8104, INSERM U1016, OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Université de Paris, Paris, France. olivier.kosmider@inserm.fr.
Assistance Publique-Hôpitaux de Paris, Centre - Université de Paris, Service d'Hématologie biologique, Hôpital Cochin, Paris, France. olivier.kosmider@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH